文献速递心境障碍

重性抑郁障碍的神经调控:捕捉疗效与结局的创新测量方法

Neuromodulation for major depressive disorder: innovative measures to capture efficacy and outcomes.
PubMed 文献 · Lancet Psychiatry · 2020-10-29

本文为个人观点文章,指出当前神经外科试验中用于评估重性抑郁障碍结局的测量工具可能遗漏临床重要的治疗效果。作者认为继续使用次优结局测量可能错过真实的疗效信号,导致潜在有效治疗被错误淘汰,因此亟需重新评估结局测量方式,并描述了若干更好捕捉有意义变化的新方法。

要点

  • 当前神经外科试验的结局测量可能遗漏重性抑郁障碍的临床重要治疗效果。
  • 使用次优结局测量可能错过真实疗效信号,使潜在有效治疗被错误淘汰。
  • 亟需重新评估神经外科试验的结局测量,并采用更好捕捉有意义变化的新方法。

核心结论

  • 当前神经外科试验中评估重性抑郁障碍结局的测量工具可能遗漏临床重要的治疗效果。
  • 继续使用次优结局测量可能错过真实疗效信号,从而使潜在有效的治疗被错误淘汰。
  • 亟需重新评估这些试验中的结局测量方式,并采用更好捕捉有意义变化的新方法。

研究设计与样本

  • 本文为Personal View(个人观点)文章,未报告系统检索范围或样本量。

主要发现

  • 当前神经外科试验的结局测量可能遗漏重性抑郁障碍的临床重要治疗效果。
  • 使用次优结局测量可能错过真实疗效信号,导致潜在有效治疗被错误淘汰。

临床怎么用

  • 在神经调控治疗重性抑郁障碍的临床试验中,应重新评估并改进结局测量以更好捕捉有意义的临床变化。

局限性

  • 本文为个人观点文章,未报告原始研究数据、样本量或系统检索方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Major depressive disorder is a common and debilitating disorder. Although most patients with this disorder benefit from established treatments, a subset of patients have symptoms that remain treatment resistant. Novel treatment approaches, such as deep brain stimulation, are urgently needed for patients with treatment-resistant major depressive disorder. These novel treatments are currently being tested in clinical trials in which success hinges on how accurately and comprehensively the primary outcome measure captures the treatment effect. In this Personal View, we argue that current measures used to assess outcomes in neurosurgical trials of major depressive disorder might be missing clinically important treatment effects. A crucial problem of continuing to use suboptimal outcome measures is that true signals of efficacy might be missed, thereby disqualifying potentially effective treatments. We argue that a re-evaluation of how outcomes are measured in these trials is much overdue and describe several novel approaches that attempt to better capture meaningful change.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Rabin JS, Davidson B, Giacobbe P, et al. Neuromodulation for major depressive disorder: innovative measures to capture efficacy and outcomes. Lancet Psychiatry. 2020. PMID: 33129374. doi:10.1016/S2215-0366(20)30187-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。